- NEWS AND VIEWS
Immune-cell crosstalk in multiple sclerosis
Access options
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$199.00
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
Nature 563, 194-195 (2018)
doi: https://doi.org/10.1038/d41586-018-07063-z
References
Wekerle, H. Acta Neurol. Scand. 136 (Suppl. 201), 22–25 (2017).
Jelcic, I. et al. Cell 175, 85–100 (2018).
Mohme, M. et al. Brain 136, 1783–1798 (2013).
Oksenberg, J. R., Baranzini, S. E., Sawcer, S. & Hauser, S. L. Nature Rev. Genet. 9, 516–526 (2008).
Panitch, H. S., Hirsch, R. L., Haley, A. S. & Johnson, K. P. Lancet 329, 893–895 (1987).
Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Brain 123, 1174–1183 (2000).
Bruck, W. et al. Immunobiology 195, 588–600 (1996).
Hendriks, R. W., Yuvaraj, S. & Kil, L. P. Nature Rev. Cancer 14, 219–232 (2014).
Mertin, J. Proc. R. Soc. Med. 70, 871–874 (1977).
Greenfield, A. L. & Hauser, S. L. Annls Neurol. 83, 13–26 (2018).
Hauser, S. L. et al. N. Engl. J. Med. 358, 676–688 (2008).
Wekerle, H. Autoimmunity 50, 57–60 (2017).
Kivisäkk, P. et al. Clin. Exp. Immunol. 129, 510–518 (2002).
Restorick, S. M. et al. Brain Behav. Immun. 64, 71–79 (2017).
Richert, J. R., McFarlin, D. E., Rose, J. W., McFarland, H. F., Greenstein, J. I. J. Neuroimmunol. 5, 317–324 (1983).
Competing Interests
R. M. R. was employed by Biogen, the manufacturer of natalizumab, from October 2014 to November 2017. He retains a small equity interest in Biogen.